The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

NCT06606821 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of tirzepatide, a medication, in adults who have overweight or obesity along with coronary artery disease.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 124 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-10 · est. completion 2028-08

Where 3 sites · Denmark

What this study is testing ClinicalTrials.gov NCT06606821 ↗

Description as written by the study sponsor.

The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Investigational drug will be administered as a sc. injection once-weekly.
Placebo also known as Saline Drug

Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.

Main thing measured	Lipid core burden index
Sponsor	Tina Vilsbøll
Conditions studied	Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06606821 ↗